Data as of Q4 2025 (Dec 31, 2025)

Tri Locum Partners LP

โ€ขCIK: 1826434โ€ขFiling: Q4 2025

**Tri Locum Partners LP** manages $770M across a concentrated portfolio of 15 positions. The fund exhibits significant overweighting in the healthcare sector, evidenced by top holdings including JNJ at $124.8M and DHR at $79.4M. Key allocations also feature LLY ($68.0M) and UTH ($58.9M), suggesting a focused, defensive mandate within large-cap biopharma and healthcare services. This structure indicates a conviction-driven approach targeting established, sector-leading names.

Total AUM
$770.1M
QoQ Performance
+77.0%
Positions
15
Top 10 Concentration
80.1%
Latest Filing
Q4 2025

Top Holdings Allocation

JNJ
DHR
LLY
UTH
ASND
MDGL
BSX
TEVA
JNJ16.2%
DHR10.3%
LLY8.8%
UTH7.7%
ASND7.3%
MDGL6.5%
BSX6.4%
TEVA5.8%

๐Ÿ“ˆ Biggest Buys

DHR
DANAHER CORPORATION
NEW
10.3% of portfolio
LLY
ELI LILLY & CO
NEW
8.8% of portfolio
JNJ
JOHNSON & JOHNSON
+99.2%
16.2% of portfolio
BSX
BOSTON SCIENTIFIC CORP
NEW
6.4% of portfolio
TEVA
TEVA PHARMACEUTICAL INDS LTD
NEW
5.8% of portfolio

๐Ÿ“‰ Biggest Sells

VERA
VERA THERAPEUTICS INC
-32.3%
5.3% of portfolio
AXSM
AXSOME THERAPEUTICS INC
-31.0%
4.8% of portfolio
ARGX
ARGENX SE
-13.3%
4.1% of portfolio
UTH
UNITED THERAPEUTICS CORP DEL
-1.0%
7.7% of portfolio

Sector Breakdown

Other64.7%
Healthcare35.3%

๐Ÿšช Exited Positionssold since Q3 2025

MRK
MERCK & CO INC
SOLD
$37.5M
SLNO
SOLENO THERAPEUTICS INC
SOLD
$30.5M
ABBV
ABBVIE INC
SOLD
$20.8M
KRRO
KORRO BIO INC
SOLD
$16.2M
XENE
XENON PHARMACEUTICALS INC
SOLD
$14.7M
+5 more exited positions

Changes from Q3 2025

NEW7 new positions
โ†‘4 increased
โ†“4 decreased

Historical Filings

Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023